Results 221 to 230 of about 420,474 (296)

Destiny

, 1992
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Lancet, The, 2023
BACKGROUND In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan showed robust activity in patients with HER2-positive metastatic breast cancer who were refractory or resistant to trastuzumab emtansine; a population with scarce ...
Manuel Ruiz Borrego
exaly   +2 more sources

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

The Lancet Oncology, 2021
BACKGROUND HER2 amplification has been identified in 2-3% of patients with colorectal cancer, although there are currently no approved HER2-targeted therapies for colorectal cancer.
S. Siena, M. Di Bartolomeo, K. Raghav, T. Masuishi, F. Loupakis, H. Kawakami, K. Yamaguchi, T. Nishina, M. Fakih, E. Élez, Javier Rodríguez, F. Ciardiello, Y. Komatsu, T. Esaki, K. Chung, Z. Wainberg, A. Sartore-Bianchi, K. Saxena, E. Yamamoto, E. Bako, Y. Okuda, J. Shahidi, A. Grothey, T. Yoshino   +23 more
semanticscholar   +1 more source

Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02

Cancer Research, 2023
In DESTINY-Breast01 (NCT03248492) and DESTINY-Breast03 (NCT03529110), trastuzumab deruxtecan (T-DXd) demonstrated unprecedented activity in patients (pts) with HER2+ (immunohistochemistry 3+; immunohistochemistry 2+/in situ hybridization+) advanced ...
I. Krop, Yeon-Hee Park, Sung-Bae Kim, G. Borges, S. Aksoy, J. G. Gregori, R. Roylance, E. Lim, R. Yerushalmi, F. Zagouri, F. Duhoux, T. Fehm, T. Takano, A. Egorov, I-Wei K. Wu, J. Cathcart, Chang Chu, F. André   +17 more
semanticscholar   +1 more source

Are Reindeer the New Buffalo? Climate Change, the Green Shift, and Manifest Destiny in Sápmi

Social Science Research Network, 2023
:In the nineteenth-century prairies, the buffalo was nearly exterminated as the result of the European economic and ecological invasion. Today in Scandinavia, reindeer are being threatened by the renewable energy transition, also known as the Green Shift.
R. Kuokkanen
semanticscholar   +1 more source

Struggling with Destiny in Karimpur, 1925-1984

, 2023
Susan Wadley first visited Karimpur - the village 'behind mud walls' made famous by William and Charlotte Wiser - as a graduate student in 1967. She returned often, adding her observations and experiences to the Wisers' field notes from the 1920s and ...
S. Wadley
semanticscholar   +1 more source

An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.

Journal of Clinical Oncology, 2023
1006 Background: T-DXd is approved for use in pts with HER2+ unresectable or mBC after a prior anti-HER2-based regimen in the metastatic or (neo)adjuvant setting, based on the randomized phase 3 DESTINY-Breast03 study (Cortes et al.
I. Krop, H. Wildiers, S. Hurvitz, J. Cortés, S. Im, H. Iwata, F. André, C. Saura, S. Modi, Sung-Bae Kim, A. Egorov, Elton Mathias, J. Cathcart, A. Cagnazzo, Yingkai Cheng, Yeon-Hee Park   +15 more
semanticscholar   +1 more source

Manifest Destiny

America’s Road to Empire, 2022
The whites are the winning race, not only in North America. It is the tradition in the USA to call this phenomenon 'Manifest Destiny'. Christians used to believe that Jesus helped the Europeans to conquer the New World.
J. Tyler
semanticscholar   +1 more source

Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

Journal of Clinical Oncology, 2021
526 Background: Patients (pts) with HER2+ metastatic breast cancer (mBC) are at high risk of developing brain metastases (BMs), and treatment options are limited once BMs occur.
G. Jerusalem, Yeon-Hee Park, T. Yamashita, S. Hurvitz, S. Modi, F. André, I. Krop, X. Gonzàlez, P. Hall, B. You, C. Saura, Sung-Bae Kim, C. Osborne, Y. Sagara, E. Tokunaga, Yali Liu, J. Cathcart, Caleb Lee, C. Perrin   +18 more
semanticscholar   +1 more source